Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors

• Published in: The Medical clinics of North America Vol. 107; no. 3; p. 623
• Main Authors: Bessone, Fernando, Björnsson, Einar S
• Format: Journal Article
• Language: English
• Published: United States 01.05.2023
• Subjects: Adalimumab - adverse effects; Antibodies, Monoclonal - adverse effects; Antirheumatic Agents - therapeutic use; Biological Products - adverse effects; Chemical and Drug Induced Liver Injury - diagnosis; Chemical and Drug Induced Liver Injury - drug therapy; Chemical and Drug Induced Liver Injury - etiology; Etanercept - adverse effects; Humans; Infliximab - adverse effects; Interleukin 1 Receptor Antagonist Protein - therapeutic use; Receptors, Tumor Necrosis Factor - therapeutic use; Tumor Necrosis Factor-alpha; Checkpoint inhibitors; Hepatitis; Drug-induced liver injury; Hepatotoxicity; Biologics
• ISSN: 1557-9859
• DOI: 10.1016/j.mcna.2022.12.008

Biological agents have in the last two decades become very important therapeutic agents, particularly for the treatment of various autoimmune disorders. The most widely used biologics are the tumor necrosis factor-α (TNF-α) receptor antagonists: infliximab, adalimumab, and etanercept. Other commonly used biological agents are interleukin (IL)-1 receptor antagonist (Anakinra), interleukin (IL)-6 receptor antagonist (tocilizumab), and CD20 surface antigen antagonist (rituximab). The current review will however focus on TNF-α receptor antagonists.